Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in TIO or ENS-Associated Osteomalacia
NCT02304367Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of burosumab in tumor-induced osteomalacia (TIO), epidermal nevus syndrome (ENS), sponsored by Kyowa Kirin. Started Mar 2015; status: completed.
02
Drugs
burosumab
03
Conditions
tumor-induced osteomalacia (TIO)epidermal nevus syndrome (ENS)
Beyond the preview
Go deeper on NCT02304367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304367.